echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Fatal complications of transplant surgery welcomes first approved therapy FDA approved BMS CTLA-4 fusion protein

    Fatal complications of transplant surgery welcomes first approved therapy FDA approved BMS CTLA-4 fusion protein

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 15, 2021, the US FDA announced the approval of Orencia (abatacept)'s supplementary biological product license application (sBLA) for use in combination with certain immunosuppressive agents to prevent acute graft-versus-host in children or adult patients over 2 years old Disease (aGVHD)


    HSCT is an effective method for the treatment of aggressive leukemia and other hematological malignancies, and is usually the only option for cure


    GVHD occurs when donor T cells recognize the patient's healthy cells as foreign objects and start to attack


    This approval is based on the results of a Phase 2 clinical trial and a study based on real-world data


    Note: The original text has been deleted

    Reference materials:

    [1] FDA Approves First Drug to Prevent Graft Versus Host Disease.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.